肿瘤相关中性粒细胞在免疫检查点抑制剂耐药中的研究进展

doi:10.11904/j.issn.1002-3070.2024.05.011

Abstract

Abstract: Cancer is a major disease that seriously endangers human health.In recent years,immune checkpoint inhibitors(ICIs)have changed the paradigm of treatment for various solid tumors.Although the initial treatment effect is significant,the issue of drug resistance in this therapy has gradually become apparent.It is particularly important to have a deep understanding of the mechanisms of ICIs resistance.Neutrophils in the tumor microenvironment(TME)play a critical role in the resistance of programmed cell death protein-1(PD-1)and its ligand inhibitors.Thus,remodeling tumor-associated neutrophils(TANs)can not only enhance the anti-tumor immune response,but also contribute to improving patient prognosis.This article aims to explore the potential role of TANs in ICIs resistance and summarize current efforts to overcome ICIs resistance.

Key words: Tumor-associated neutrophils, Immune checkpoint inhibitors, Drug resistance

CLC Number:

R730.5

HAN Jing, GUAN Quanlin. Research progress of tumor-associated neutrophils in immune checkpoint inhibitors resistance[J]. Journal of Practical Oncology, 2024, 38(5): 349-354.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I5/349

References

1 Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
2 Debela DT,Muzazu SG,Heraro KD,et al.New approaches and procedures for cancer treatment:current perspectives[J].SAGE Open Med,2021,9:20503121211034366.
3 Ribas A,Wolchok JD.Cancer immunotherapy using checkpoint blockade[J].Science,2018,359(6382):1350-1355.
4 Huang Z,Su W,Lu T,et al.First-line immune-checkpoint inhibitors in non-small cell lung cancer:current landscape and future progress[J].Front Pharmacol,2020,11:578091.
5 Cohen EEW,Soulières D,Le Tourneau C,et al.Pembrolizumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma(KEYNOTE-040):a randomised,open-label,phase 3 study[J].Lancet,2019,393(10167):156-167.
6 Bagchi S,Yuan R,Engleman EG.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance[J].Annu Rev Pathol,2021,16(1):223-249.
7 Wang Z,Wang Y,Gao P,et al.Immune checkpoint inhibitor resistance in hepatocellular carcinoma[J].Cancer Lett,2023,555:216038.
8 Genova C,Dellepiane C,Carrega P,et al.Therapeutic implications of tumor microenvironment in lung cancer:focus on immune checkpoint blockade[J].Front Immunol,2022,12:799455.
9 Faget J,Peters S,Quantin X,et al.Neutrophils in the era of immune checkpoint blockade[J].J Immunother Cancer,2021,9(7):e002242.
10 Zhang X,Shi H,Yuan X,et al.Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration[J].Mol Cancer,2018,17(1):146.
11 Hattar K,Franz K,Ludwig M,et al.Interactions between neutrophils and non-small cell lung cancer cells:enhancement of tumor proliferation and inflammatory mediator synthesis[J].Cancer Immunol Immunother,2014,63(12):1297-1306.
12 Peng W,Sheng Y,Xiao H,et al.Lung adenocarcinoma cells promote self-migration and self-invasion by activating neutrophils to upregulate notch3 expression of cancer cells[J].Front Mol Biosci,2022,8:762729.
13 Sagiv JY,Michaeli J,Assi S,et al.Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer[J].Cell Rep,2015,10(4):562-573.
14 Shaul ME,Fridlender ZG.Tumour-associated neutrophils in patients with cancer[J].Nat Rev Clin Oncol,2019,16(10):601-620.
15 Wu L,Saxena S,Awaji M,et al.Tumor-associated neutrophils in cancer:going pro[J].Cancers,2019,11(4):564.
16 Bui TM,Yalom LK,Sumagin R.Tumor-associated neutrophils:orchestrating cancer pathobiology and therapeutic resistance[J].Expert Opin Ther Targets,2021,25(7):573-583.
17 Kwantwi LB.Interplay between tumor-derived factors and tumor-associated neutrophils:opportunities for therapeutic interventions in cancer[J].Clin Transl Oncol,2023,25(7):1963-1976.
18 Kamran N,Kadiyala P,Saxena M,et al.Immunosuppressive myeloid cells′ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy[J].Mol Ther,2017,25(1):232-248.
19 Tang D,Zhang D,Heng Y,et al.Tumor-infiltrating PD-L1+ neutrophils induced by GM-CSF suppress T cell function in laryngeal squamous cell carcinoma and predict unfavorable prognosis[J].J Inflamm Res,2022,15:1079-1097.
20 Sun R,Xiong Y,Liu H,et al.Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis[J].Transl Oncol,2020,13(10):100825.
21 Shang A,Wang W,Gu C,et al.Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils[J].J Exp Clin Cancer Res,2019,38(1):411.
22 Wang TT,Zhao YL,Peng LS,et al.Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway[J].Gut,2017,66(11):1900-1911.
23 Shi Y,Zhang J,Mao Z,et al.Extracellular vesicles from gastric cancer cells induce PD-L1 expression on neutrophils to suppress T-cell immunity[J].Front Oncol,2020,10:629.
24 Cheng Y,Li H,Deng Y,et al.Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma[J].Cell Death Dis,2018,9(4):422.
25 He G,Zhang H,Zhou J,et al.Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma[J].J Exp Clin Cancer Res,2015,34(1):141.
26 Arasanz H,Bocanegra AI,Morilla I,et al.Circulating low density neutrophils are associated with resistance to first line Anti-PD1/PDL1 immunotherapy in non-small cell lung cancer[J].Cancers,2022,14(16):3846.
27 Wong SL,Wagner DD.Peptidylarginine deiminase 4:a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging[J].FASEB J,2018,32(12):6258-6370.
28 Brinkmann V,Reichard U,Goosmann C,et al.Neutrophil extracellular traps kill bacteria[J].Science,2004,303(5663):1532-1535.
29 Teijeira á,Garasa S,Gato M,et al.CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity[J].Immunity,2020,52(5):856-871.
30 Wang R,Zhu Y,Liu Z,et al.Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke[J].Blood,2021,138(1):91-103.
31 Chen D,Li Q,Liang H,et al.Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps[J].Biochem Biophys Res Commun,2022,619:97-103.
32 Zhang H,Wang Y,Onuma A,et al.Neutrophils extracellular traps inhibition improves PD-1 blockade immunotherapy in colorectal cancer[J].Cancers,2021,13(21):5333.
33 Zhang Y,Chandra V,Riquelme Sanchez E,et al.Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer[J].J Exp Med,2020,217(12):e20190354.
34 Akbay EA,Koyama S,Liu Y,et al.Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade[J].J Thorac Oncol,2017,12(8):1268-1279.
35 Kim GT,Kim EY,Shin SH,et al.Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma[J].BMC Cancer,2022,22(1):727.
36 Simoncello F,Piperno GM,Caronni N,et al.CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors[J].Oncoimmunology,2022,11(1):2059876.
37 Sun L,Clavijo PE,Robbins Y,et al.Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy[J].JCI Insight,2019,4(7):e126853.
38 D′Alterio C,Barbieri A,Portella L,et al.Inhibition of stromal CXCR4 impairs development of lung metastases[J].Cancer Immunol Immunother,2012,61(10):1713-1720.
39 Bockorny B,Semenisty V,Macarulla T,et al.BL-8040,a CXCR4 antagonist,in combination with pembrolizumab and chemotherapy for pancreatic cancer:the COMBAT trial[J].Nat Med,2020,26(6):878-885.
40 Kaunisto A,Henry WS,Montaser-Kouhsari L,et al.NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer[J].Mol Oncol,2015,9(6):1140-1154.
41 Cai Z,Zhang M,Boafo Kwantwi L,et al.Breast cancer cells promote self-migration by secreting interleukin 8 to induce NET formation[J].Gene,2020,754:144902.
42 Denk S,Taylor RP,Wiegner R,et al.Complement C5a‐induced changes in neutrophil morphology during inflammation[J].Scand J Immunol,2017,86(3):143-155.
43 Allen E,Jabouille A,Rivera LB,et al.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation[J].Sci Transl Med,2017,9(385):9679.
44 Ott PA,Hodi FS,Buchbinder EI.Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma:an overview of rationale,preclinical evidence,and initial clinical data[J].Front Oncol,2015,5:202.
45 Taylor MH,Lee CH,Makker V,et al.Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma,endometrial cancer,and other selected advanced solid tumors[J].J Clin Oncol,2020,38(11):1154-1163.
46 Amin A,Plimack ER,Ernstoff MS,et al.Correction to:safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma:the checkmate 016 study[J].J Immunother Cancer,2019,7(1):73.
47 Kauder SE,Kuo TC,Harrabi O,et al.ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile[J].Plos One,2018,13(8):e0201832.
48 Lakhani NJ,Chow LQM,Gainor JF,et al.Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours(ASPEN-01):a first-in-human,open-label,multicentre,phase 1 dose-escalation and dose-expansion study[J].Lancet Oncol,2021,22(12):1740-1751.
49 Ansell SM,Maris MB,Lesokhin AM,et al.Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies[J].Clin Cancer Res,2021,27(8):2190-2199.
50 Bockorny B,Macarulla T,Semenisty V,et al.Motixafortide and pembrolizumab combined to nanoliposomal irinotecan,fluorouracil,and folinic acid in metastatic pancreatic cancer:the COMBAT/KEYNOTE-202 trial[J].Clin Cancer Res,2021,27(18):5020-5027.
51 Andtbacka RHI,Wang Y,Pierce RH,et al.Mavorixafor,an orally bioavailable CXCR4 antagonist,increases immune cell infiltration and inflammatory status of tumor microenvironment in patients with melanoma[J].Cancer Res Commun,2022,2(8):904-913.
52 Choueiri TK,Atkins MB,Rose TL,et al.A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy[J].Invest New Drugs,2021,39(4):1019-1027.
53 Armstrong AJ,Geva R,Chung HC,et al.CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors:a phase 2 randomized trial[J].Invest New Drugs,2024,42(1):145-159.
54 Garrido P,Pujol JL,Kim ES,et al.Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer:CANOPY-N study design[J].Future Oncol,2021,17(12):1459-1472.
55 Tan DSW,Felip E,de Castro G,et al.Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer:results from the CANOPY-1 trial.[J].J Clin Oncol,2024,42(2):192-204.
56 Chen IM,Donia M,Chamberlain CA,et al.Phase 2 study of ipilimumab,nivolumab,and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer(TRIPLE-R)[J].Eur J Cancer,2023,180:125-133.
57 Munster P,Iannotti N,Cho DC,et al.Combination of itacitinib or parsaclisib with pembrolizumab in patients with advanced solid tumors:a phase I study[J].Cancer Res Commun,2023,3(12):2572-2584.

[1]	HE Jiaying, ZHU Jinli, JIA Kaixuan, YANG Peiying. Research progress of IFN-γ in the treatment of tumor immune checkpoint inhibitors [J]. Journal of Practical Oncology, 2024, 38(5): 330-335.
[2]	ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors [J]. Journal of Practical Oncology, 2024, 38(1): 55-61.
[3]	SHANG Hongyue, YAO Manman, LU Yueting, WANG Dixian, ZHAO Qian, LIU Tiejun. Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance [J]. Journal of Practical Oncology, 2024, 38(1): 67-70.
[4]	CAO Xinyu, ZHOU Xu, WANG Quan, JIANG Wei. Potential mechanisms and prediction methods of anticancer drug resistance [J]. Journal of Practical Oncology, 2023, 37(6): 491-495.
[5]	ZHANG Yan, TIAN Suli, ZHOU Yongxu, LIU Chang. Regulating mechanism of miR-7 in sensitivity of colorectal cancer cells to 5-fluorouracil [J]. Journal of Practical Oncology, 2023, 37(4): 320-328.
[6]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[7]	FENG Chengtian, HUANG Furong, JIANG Yongdong. Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 155-159.
[8]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[9]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[10]	LI Zhihui, LI Zhigao. Research progress of T-DM1 in treatment of HER2 positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 477-482.
[11]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[12]	YU Chengping, CUI Yongkang, LI Linqiang. Research progress of eccDNA in cancer [J]. Journal of Practical Oncology, 2022, 36(3): 255-258.
[13]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[14]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[15]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.

Research progress of tumor-associated neutrophils in immune checkpoint inhibitors resistance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments